Opinion|Videos|May 6, 2024 (Updated: May 6, 2024)
Importance of Early Diagnosis of Alzheimer’s Disease
Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Discuss the importance of early diagnosis and treatment of Alzheimer’s disease.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.
Here's some of what is coming soon to NeurologyLive® this week.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.
Seven investigational cerebral palsy therapies—from baby-tooth stem cells to cannabinoids and botulinum toxin—show mixed early results, highlighting key clinical trial milestones ahead.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease
2
LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease
3
GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease
4
Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease
5